The US is the largest healthcare market in the world and where we see the greatest opportunity.
We intend to leverage our platform technologies dCELL® and BioRinse™ to further our market penetration through a hybrid sales model, a combination of direct sales, distribution and OEM agreements.
At the beginning of 2018 we revised our commercial strategy with a focus on establishing and building strategic partnerships to further our market access and penetration
This also allows for the potential to increase OEM agreements and initiate discussions around joint IP collaborations.
Our success is reliant upon the ability to commercialise our current portfolio and the potential for augmenting this with line extensions and new innovative products.
We therefore look to establish a database of compelling real world clinical data to validate our technology platforms and further our physician conversion rates.
These clinical data portfolios are also imperative when we seek new strategic partnership opportunities and when navigating regulatory clearance in new territories.
Our current commercialisation efforts are focused on the US markets; however, there is the opportunity and market demand for us to enter new territories.